MedTrace Logo

Different Vitamin D Preparations & FGF23 in Humans

NCT00957879 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-04-19

No results posted yet for this study

Summary

Fibroblast growth factor 23 (FGF23) is a new hormone which controls phosphate and vitamin D levels in humans. Excess FGF23 is associated with an increased risk of death in patients with chronic kidney disease. In this study the investigators are investigating the effects of different forms of vitamin D on FGF23 levels in the blood in order to increase our understanding of how this important hormone works.

Conditions

  • Vitamin D Deficiency

Interventions

DIETARY_SUPPLEMENT

Ergocalciferol

Ergocalciferol 50000 international units by mouth weekly for 12 weeks

DIETARY_SUPPLEMENT

Calcitriol

Calcitriol 0.5 mcg by mouth daily for 12 weeks

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Sherri-Ann M Burnett-Bowie, MD, MPH · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-09-30
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00957879 on ClinicalTrials.gov